Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scuttle the forward momentum? On the latest BioCentury This Week podcast, BioCentury’s analysts take the temperature of the markets for biotech." They also discuss last week’s late-stage epilepsy data from Xenon Pharmaceuticals, which revived the biotech’s stock and the Kv7 target. And, in a Rare Disease Spotlight, BioCentury’s analysts discuss how Friedreich ataxia is moving into a mechanistic second act , with biotechs pivoting from stabilizing the mitochondrial damage caused by frataxin loss to developing therapies designed to fix the gene itself. View full story: 00:00 - Introduction 03:23 - Market Sentiment 09:58 - Xenon Phase III Win 18:03 - Friedreich Ataxia Pipeline To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

You can listen to Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline online on Radio and Podcast. Open the player on this page to stream the available audio.

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline is an episode from BioCentury This Week by BioCentury.

This episode is 24:40 long.

This episode was published on Mar 17, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BioCentury This Week when more episodes are available from the podcast feed.